We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current 0JGL market cap is 1.9B. The company's latest EPS is NOK -0.5443 and P/E is -93.70.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | |
| Total Revenue | 9.39M | 9.37M | 6.27M | 4.75M | 2.99M |
| Operating Income | -88.8M | -80.12M | -86.03M | -56.45M | -22.24M |
| Net Income | -88.75M | -70.24M | -88.39M | -55.1M | -20.32M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | |
| Total Assets | 282.03M | 209.12M | 135.98M | 63.48M | 44.05M |
| Total Liabilities | 27.2M | 19.88M | 22.19M | 6.08M | 5.01M |
| Total Equity | 254.83M | 189.24M | 113.79M | 57.4M | 39.04M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | |
| Operating | -83.47M | -77.39M | -68.31M | -59.04M | -15.07M |
| Investing | -3.63M | -3.92M | -341k | N/A | N/A |
| Financing | 526k | -352k | -673k | -678k | -340k |
| Market Cap | 1.9B |
| Price to Earnings Ratio | -93.70 |
| Price to Sales Ratio | 636.7 |
| Price to Cash Ratio | 46.22 |
| Price to Book Ratio | 48.76 |
| Dividend Yield | - |
| Shares Outstanding | 37.33M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 0.00% |
| 52 Week High | 51.00 |
| 52 Week Low | 51.00 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Pci Biotech Holding Asa |
| Address |
strandveien 55 lysaker N-1366 |
| Website | https://www.pcibiotech.no |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
